Revenue distribution by sectors:

• Orthopedics: approx. 40%
• Medical Technology & Surgery: approx. 35%
• Neurotechnology & Spine: approx. 25%

TOP 3 markets and their percentage shares:

• USA: approx. 65%
• Europe: approx. 20%
• Asia-Pacific: approx. 10%

Stryker Corporation generates the majority of its revenue from orthopedics, followed by medical technology and surgery, and neurotechnology and spine. The U.S. market is the dominant market for Stryker, attributed to the strong presence and demand for medical devices in the United States. Europe and the Asia-Pacific region are also significant markets, with Europe having a larger share of revenue than the Asia-Pacific region.

Production Sites: Several countries worldwide, including the USA, Ireland, Germany, and China.

Stryker Corporation is a globally operating company in the field of medical technology and produces its products at various locations worldwide. The main production facilities are located in the USA, especially in Michigan and California. In addition, Stryker has established significant production capacities in Ireland, Germany, and China to efficiently serve the demand in different markets.

This geographical diversification enables Stryker to minimize supply chain risks and optimize production costs while ensuring proximity to key markets.

Revenue Growth: Estimated 8-10% annually (2025)

Research and Development Investments: Over 1 billion USD annually (2025)

Stryker Corporation pursues a growth strategy that heavily relies on innovation and expansion into new markets. The company continuously invests in research and development to expand its product range and integrate new technologies. These investments amount to over 1 billion USD annually, enabling Stryker to offer innovative solutions in the field of medical technology.

Another focus is on strategic acquisitions to expand the product portfolio and strengthen market presence. In the past, Stryker has successfully acquired companies offering complementary technologies and products and plans to continue this strategy.

Additionally, Stryker is focusing on geographical expansion, especially in emerging markets, to benefit from the increasing demand for high-quality medical devices. Through these measures, the company expects sustainable revenue growth of 8-10% annually.

Main raw materials: Titanium, stainless steel, polyethylene, cobalt-chrome alloys

Countries of origin:

• Titanium: Australia, Canada
• Stainless steel: China, Germany
• Polyethylene: USA, Saudi Arabia
• Cobalt-chrome alloys: South Africa, Russia

Stryker Corporation, as a leading provider of medical technology, imports various raw materials needed for the production of medical implants and devices. Titanium and stainless steel are crucial for the manufacturing of durable and biocompatible medical products. Polyethylene is commonly used for joint prostheses, while cobalt-chrome alloys are utilized in dentistry and orthopedic implants.

The selection of countries of origin is based on the availability and quality of the raw materials as well as existing trade relationships. Stryker ensures to source raw materials from countries that can guarantee a stable supply and high quality standards.

Market share in the medical technology sector: 8% (estimated for 2025)
R&D expenses: 6.5% of revenue (2024)
Gross margin: 65% (2024)

Stryker Corporation has a significant competitive advantage in the medical technology industry. With an estimated market share of 8%, the company is among the leading providers worldwide. The continuous investments in research and development, accounting for approximately 6.5% of revenue, underscore Stryker's commitment to innovation and product development.

The high gross margin of 65% demonstrates the company's ability to sell its products at a premium price, indicating a strong brand position and efficient production processes. These factors, combined with a wide range of products and a global presence, significantly strengthen Stryker's competitive advantage.

Institutional investor share: approx. 75% (estimated for 2025 based on historical data)

Insider purchases/sales: No significant transactions in the last year (estimated)

The institutional investor share at Stryker Corporation traditionally stands at about 75%, indicating the trust of large investment funds and institutional investors in the company's stability and growth potential. These investors particularly value Stryker's strong market position in the field of medical technology.

Regarding insider purchases and sales, there have been no significant transactions in the last year that would indicate a change in management's confidence in the company's future development. Such transactions can often serve as an indicator of management's assessment of the company's future performance.

Market share of Stryker Corporation: Approx. 10% (estimated for 2025)

Main competitors and their market shares:

1. Medtronic plc: Approx. 12%
2. Johnson & Johnson (DePuy Synthes): Approx. 11%
3. Zimmer Biomet Holdings, Inc.: Approx. 9%
4. Smith & Nephew plc: Approx. 7%
5. Boston Scientific Corporation: Approx. 6%

Moat of Stryker Corporation:

Stryker Corporation has a significant moat, which consists of several factors. The company has strong brand recognition and a broad portfolio of innovative medical devices and technologies. This enables Stryker to maintain a leading position in several segments of the medical technology market.

Another advantage is the strong customer loyalty through comprehensive service and support offerings, making it difficult for hospitals and clinics to switch to another provider. Additionally, Stryker continuously invests in research and development to bring innovative products to the market, securing its technological edge.

Compared to competitors, Stryker has a comparable moat, but companies like Medtronic and Johnson & Johnson are also strongly positioned due to their size and global reach. These companies also have extensive product portfolios and heavily invest in research and development, strengthening their moat.

Overall, Stryker's moat is solid but not insurmountable, as the competition is also strong and continuously working on improving their market position.

Revenue Growth: 8.5% (2024) Profit Growth: 10.2% (2024) Market Share in the Medical Technology Industry: 12% (2024)

Stryker Corporation recorded a revenue growth of 8.5% in 2024, attributed to strong demand for its medical devices and innovative products. Profit growth was at 10.2%, highlighting the company's efficiency and cost-effectiveness.

The company holds a significant market share of 12% in the medical technology industry, demonstrating its strong market position and competitiveness. Stryker continuously invests in research and development to offer innovative solutions that meet the needs of the healthcare industry.

Stryker's long-term growth prospects are promising, especially through expansion into emerging markets and the introduction of new technologies. These factors could further strengthen the company in the coming years and make it an attractive investment opportunity.

Dividend yield: 1.1% (2025, estimated)
Dividend growth: 9% annually (last 5 years)

Stryker Corporation regularly pays out a dividend. The current dividend yield is approximately 1.1%, which is moderate compared to other companies in the medical technology industry.

The reliability of Stryker's dividend payments is high, as the company has seen a steady dividend growth of an average of 9% per year in recent years. This reflects solid financial health and strong operational performance.

Stryker has a long tradition of dividend payments and is committed to continuing this in the future, supported by a conservative payout ratio and strong cash flow management.